Who to call at Akari Therapeutics, plc, and when
Fundz watches for the moments Akari Therapeutics, plc starts buying, and tells you who to reach.
- An alert the day Akari Therapeutics, plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Akari Therapeutics, plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Akari Therapeutics, plc. With Fundz connected, it knows.
Akari Therapeutics, plc
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
akaritx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Akari Therapeutics appointed Kameel Farag, former CFO of Aspen Neuroscience, as interim Chief Financial Officer on October 22, 2025, succeeding Torsten Hombeck. Farag's compensation runs through a consulting agreement with his firm, KDF Ventures LLC, which ends February 16, 2026 unless extended month-to-month, so the CFO role remains interim.
Key Takeaways
Kameel Farag was appointed interim CFO effective immediately, replacing Torsten Hombeck, whose departure was previously reported, and will serve until a successor is qualified and appointed.
Farag was CFO of Aspen Neuroscience from 2021 to 2025, where he secured over $150 million in financing and prepared the company for clinical data and a potential public offering.
3 more takeaways
Related Filings (8)
8 more filings from Akari Therapeutics, plc in the last 90 days
Filing Overview
What This Means
Akari Therapeutics, plc filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.